Central Trust Company’s NeoGenomics NEO Stock Holding History

Central Trust Company’s Portfolio NEO Stock Details NEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-300	Closed	-$3K	–	1298
2022 Q3	$3K	Sell	300 -18	-6%	-$179	﹤0.01%	1165
2022 Q2	$3K	Hold	318	–	–	﹤0.01%	1174
2022 Q1	$4K	Buy	318 +18	+6%	+$379	﹤0.01%	1179
2021 Q4	$10K	Hold	300	–	–	﹤0.01%	1057
2021 Q3	$14K	Hold	300	–	–	﹤0.01%	982
2021 Q2	$14K	Buy	+300	New	+$13.3K	﹤0.01%	957

Other funds holding NEO

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Greenhouse Funds Baltimore, Maryland $1.96B AUM 36.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Central Trust Company's NEO Position: Q4 2022 in Review

Central Trust Company sold out of NeoGenomics (NEO) in Q4 2022, closing a stake of 300 shares — an estimated $3K sold.

Central Trust Company first reported a position in NEO in Q2 2021 and held it in 6 quarters. The position peaked at $14K in Q3 2021. 242 funds tracked by Wall St. Rank hold NEO as of Q4 2022.

Central Trust Company reported no remaining NeoGenomics position as of Q4 2022 after selling out during the quarter.
Central Trust Company sold 300 NeoGenomics shares in Q4 2022, an estimated $3K.
Central Trust Company first reported a position in NeoGenomics in Q2 2021 and held it in 6 quarters.
Central Trust Company's NeoGenomics position peaked at $14K in Q3 2021.
242 funds tracked by Wall St. Rank held NeoGenomics as of Q4 2022.

Based on Central Trust Company's 13F filing for Q4 2022, filed 26 Jan 2023.